Progressive cerebral atrophy in MS

Objective: To assess the potential of registered volumetric MRI in measuring rates of atrophy in MS. Background: Pathologic and imaging studies suggest that the development of permanent neurologic impairment in MS is associated with progressive brain and spinal cord atrophy. Atrophy has been suggested as a potential marker of disease progression. Conventional atrophy measurements requiring manual outlining are time-consuming and subject to reproducibility problems. Registration of serial MRI may offer a useful alternative in that cerebral losses may be measured directly from automated subtraction of brain volumes. Methods: Twenty-six patients with MS and 26 age- and gender-matched controls had two volumetric brain MR studies 1 year apart. Baseline brain and ventricular volumes were measured using semiautomated techniques, and follow-up scans were registered to baseline. Rates of cerebral atrophy were calculated directly from the registered scans. Results: Baseline brain volumes in the MS group were smaller (mean difference 78 mL [95% CI 13 to 143; p = 0.02]) and ventricular volumes greater (mean difference 12 mL [95% CI 6 to 18; p < 0.001]) than controls. The rate of cerebral atrophy in the MS group (0.8% per year) was over twice that of controls (0.3%), and the rate of ventricular enlargement was five times greater than the controls (1.6 versus 0.3 mL/year). Conclusion: Progressive cerebral atrophy is an important feature of MS. Registration-based measurements are sensitive and reproducible, allowing progressive atrophy to be detected within 1 year and may have potential as a marker of progression in monitoring therapeutic trials.

[1]  T. Hammeke,et al.  Chronic progressive multiple sclerosis. Relationship between cerebral ventricular size and neuropsychological impairment. , 1985, Archives of neurology.

[2]  Nick C Fox,et al.  Visualisation and quantification of rates of atrophy in Alzheimer's disease , 1996, The Lancet.

[3]  U. Roessmann,et al.  Analysis of brain weight. II. Adult brain weight in relation to body height, weight, and surface area. , 1980, Archives of pathology & laboratory medicine.

[4]  S. Reingold,et al.  The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.

[5]  D R Fish,et al.  Methods for normalization of hippocampal volumes measured with MR. , 1995, AJNR. American journal of neuroradiology.

[6]  W. Jagust,et al.  Brain atrophy as a surrogate marker in MS , 2000, Neurology.

[7]  L D Blumhardt,et al.  Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.

[8]  A J Thompson,et al.  Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. , 1996, Brain : a journal of neurology.

[9]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[10]  J. Koziol,et al.  Cladribine in treatment of chronic progressive multiple sclerosis , 1994, The Lancet.

[11]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[12]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[13]  G. Comi,et al.  Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis , 1993, Journal of the Neurological Sciences.

[14]  Lublin Fd,et al.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .

[15]  V. Haughton,et al.  Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.

[16]  G. Barker,et al.  Spinal cord atrophy and disability in MS , 1998, Neurology.

[17]  J. Koziol,et al.  A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. , 1999, Proceedings of the Association of American Physicians.

[18]  A. Thompson,et al.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. , 1996, Brain : a journal of neurology.

[19]  F. Barkhof,et al.  Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. , 1998, Brain : a journal of neurology.

[20]  J K Udupa,et al.  Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.

[21]  Massimo Filippi,et al.  Quantitative volumetric analysis of brain magnetic resonance imaging from patients with multiple sclerosis , 1998, Journal of the Neurological Sciences.

[22]  L Bozzao,et al.  SPECT, MRI and cognitive functions in multiple sclerosis. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[23]  J V Straumfjord,et al.  Analysis of brain weight. I. Adult brain weight in relation to sex, race, and age. , 1980, Archives of pathology & laboratory medicine.

[24]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[25]  Nick C Fox,et al.  Accurate registration of serial 3D MR brain images and its application to visualizing change in neurodegenerative disorders. , 1996, Journal of computer assisted tomography.

[26]  M N Rossor,et al.  Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. , 2000, Archives of neurology.

[27]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[28]  E D Acheson,et al.  Epidemiology of multiple sclerosis. , 1977, British medical bulletin.

[29]  D. Li,et al.  Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis , 1994, Annals of neurology.

[30]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[31]  J. Hajnal,et al.  A Registration and Interpolation Procedure for Subvoxel Matching of Serially Acquired MR Images , 1995, Journal of computer assisted tomography.

[32]  Nick C Fox,et al.  Brain atrophy progression measured from registered serial MRI: Validation and application to alzheimer's disease , 1997, Journal of magnetic resonance imaging : JMRI.

[33]  L D Blumhardt,et al.  Infratentorial atrophy on magnetic resonance imaging and disability in multiple sclerosis. , 1999, Brain : a journal of neurology.

[34]  Nick C Fox,et al.  Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. , 1997, Computer methods and programs in biomedicine.